Dr Lee Schwartzberg, MD, FACP from Renown Cancer Center discusses the emerging role of mutational analysis, immunotherapy, and antibody drug conjugates in advanced breast cancer: Testing for PI3K, ESR1, mTOR, AKT, and HER2 mutations, as well as germline BRCA1/2 mutations to allow for targeted therapy, an increasing recognition of ‘HER2-Low’ status, and a continued search for targets in advanced triple negative breast cancers.

свернуть